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Introduction
Individuals that suffer from cystic fibrosis (CF) have an
average life-span of just over 30 years, and almost all of them
die from lung disease (Boucher, 2004). The pernicious nature
of the disorder is due to the mutations in the cystic fibrosis
transmembrane regulator (CFTR) that lead to a reduction in Cl–
secretion and enhanced Na+ absorption across airway epithelia
of CF patients (Boucher, 2004). These defects in ion transport
perturb osmotic water movement leading to a reduction in the
airway-surface-liquid volume, thereby disturbing the height
and composition of the mucus and periciliary liquid layers
(Boucher, 2004). The mucus layer contains a highly
glycosylated and tangled network of mucin proteins that
normally engulfs inhaled pathogens, and then helps to expel
them from the host. In CF patients, the mucus layer thickens
in response to defective salt and fluid transport, encouraging
bacterial colonization and promoting an endobronchial
inflammatory response that ultimately destroys the lung tissue
(Boucher, 2004; Heijerman, 2005).
Cystic fibrosis is a monogenic disease, and the most
common mutation is a deletion of phenylalanine at position
508 (F508). Nevertheless, even in those patients in whom
F508 is homozygous, there is considerable variability in the
severity of CF-based lung disease that cannot be predicted
purely from CFTR genotype of an individual (Merlo and
Boyle, 2003; Boucher, 2004). This has led to a search for
epistatic genes, more recently termed ‘modifier genes’
(Boucher, 2004; Merlo and Boyle, 2003), that may either
intensify or ameliorate the disease. An improved ability to
predict phenotype from genotype, by expression analysis of
genuine modifier genes, i.e. ‘molecular profiling’ (Stoughton
and Friend, 2005), could offer new targets for more effective
CF therapy earlier in life, before lung disease is irretrievably
established (Boucher, 2004).
In the current study, we have deployed a cell biology
approach to assess the possibility whether modifier  gene
products in CF include cell-signaling and accessory proteins
that regulate the conductance of Ca2+-activated Cl– channels
(CaCCs). We have focused in this area because CaCCs conduct
Cl– ions across the plasma membrane independently of CFTR
(Kidd and Thorn, 2000; Jentsch et al., 2002; Loewen and
Forsyth, 2005). CaCCs can be activated by, for example,
purinergic agonists that are released into the extracellular space
following mechanical stimulation of cells by tidal air flow or
by coughing (Lazarowski and Boucher, 2001; Tarran et al.,
2005). These ligands bind to receptors on the luminal surface
of airway epithelia, thereby initiating phospholipase C (PLC)-
dependent release of intracellular Ca2+, activating CaCCs
(Boucher, 2004). This adaptive process is also the basis for at
least one therapeutic approach to treat CF that is currently
undergoing clinical trials; pharmacological upregulation of
salt- and fluid-secretion by stimulating CaCC activity with a
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metabolically stable purinergic agonist (Boucher, 2004;
Deterding et al., 2005). However, we have hypothesized that
the efficacy of this drug is constrained by the actions of one
particular inositol phosphate, inositol (3,4,5,6)-
tetrakisphosphate [Ins(3,4,5,6)P4] (Ho and Shears, 2002).
Ins(3,4,5,6)P4 accumulates following the activation of PLC
(Menniti et al., 1990; Carew et al., 2000) and has been shown
to inhibit certain CaCCs (Ismailov et al., 1996; Xie et al., 1996;
Carew et al., 2000; Ho et al., 2001). On the other hand, not all
CaCCs are regulated by Ins(3,4,5,6)P4 (Sasakawa et al., 1994;
Ho and Shears, 2002) nor has it previously been demonstrated
that airway epithelia use Ins(3,4,5,6)P4 to regulate Cl–
secretion.
Thus, our first goal in the current study was to determine
whether Ins(3,4,5,6)P4 can inhibit Cl– secretion in an airway-
epithelial-cell model. For these experiments, we have used the
immortalized wild-type (WT) and CF murine tracheal
epithelial (MTE) cell lines described previously (Tarran et al.,
2002). The selection of this model also enabled us to pursue
earlier observations that are directly pertinent to our separate
goal of identifying genes that influence the severity of the CF
condition (see above): CaCC activity in receptor-activated CF
MTEs is greater than that in WT MTEs (Tarran et al., 2002;
Thomas et al., 2000). This upregulation of CaCC activity is
also typical of the human CF condition (Clarke et al., 1994;
Grubb et al., 1994; Paradiso et al., 2001; Ribeiro et al., 2005;
Mall et al., 2003). In humans, this in part reflects an
inflammation-dependent expansion of the apical network of the
endoplasmic reticulum in response to chronic luminal airway
infection, which increases the capacity of cellular Ca2+ stores
(Ribeiro et al., 2005). However, this is an effect that is
environmental rather than epistatic in origin. A different
phenomenon was the basis for our interest in identifying
potential modifier genes. Previous work indicated that,
independent of the magnitude of PLC-initiated Ca2+ signals,
Cl– conductance via CaCCs was inherently higher in CF MTEs
compared with WT MTEs (Tarran et al., 2002). The molecular
basis for this particular effect has not previously been
characterized. In this study we demonstrate that genetically
based variability in the strength of the Ins(3,4,5,6)P4-signaling
system can contribute to this elevated conductance of CaCCs
in CF MTEs. Such an effect represents a demonstration that
ITPK1 is a potential modifier gene; variability in its degree of
expression may contribute to the severity of the CF condition
and may affect CF-drug efficacy.
Results
Ins(3,4,5,6)P4 inhibits Cl– secretion from tracheal
epithelial monolayers
Transepithelial Cl– secretion was measured as an increase in
electrogenic ion transport (ISC) across a polarized monolayer
from the basolateral to apical chambers of the Ussing apparatus
(Fig. 1). In these experiments, we recorded the response to a
maximally effective dose of UTP (100 M) (Tarran et al.,
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Fig. 1. Ins(3,4,5,6)P4 inhibits Ca2+-
dependent Cl– secretion across WT and
CF MTE monolayers. (A-D) ISC across
WT (blue traces) and CF (red traces)
MTE monolayers was measured as
described in Materials and Methods.
Incubation time was set to zero at the
point at which UTP (100 M) was
added to the apical chamber. Where
indicated, Bt2Ins(3,4,5,6)P4/PM and
Bt2Ins(1,4,5,6)P4/PM were added to the
apical chamber of the Ussing apparatus
at a concentration of 50 M, 2 hours
prior to the addition of UTP. KN93 was
added at a concentration of 5 M, 2
hours prior to UTP addition.
Representative traces are shown in A-D.
(E) Graphs show the average height of
ISC peaks for the various experiments
(mean ± s.e.m. of 4-6 determinations).
Numbers above each bar indicate its
percentage value relative to vehicle-
treated cells within the same group












2002). In WT MTEs (Fig. 1A, blue line), UTP quickly initiated
a rapid rise in ISC that peaked after 20-25 seconds. ISC then
declined back to the baseline, by typically no more than 150
seconds after the addition of UTP (Fig. 1). The height of the
peak was found to be directly proportional to total ISC,
calculated by integrating the area under the curve (data not
shown). Verification that ISC solely represents changes in Cl–
secretion came from control experiments, in which Cl– in the
bathing media was replaced by gluconate or when Cl– channels
were pharmacologically blocked by 4,4-
diisothiocyanatostilbene-2,2-disulfonic acid (DIDS). Under
such circumstances, UTP does not alter ISC (Thomas et al.,
2000). Furthermore, addition of amiloride to the mucosal
bathing solution did not affect ISC (data not shown) (see also
Thomas et al., 2000), indicating that Na+ conductance does not
contribute to ISC.
In previous studies (Thomas et al., 2000; Tarran et al.,
2002), it was shown that UTP-dependent Cl– secretion was
elevated in CF MTEs compared with WT cells. This result
recapitulates a well-recognized observation that CaCC activity
is upregulated in the CF condition, although the molecular
basis for this effect is not well understood (Clarke et al., 1994;
Grubb et al., 1994; Paradiso et al., 2001; Ribeiro et al., 2005;
Mall et al., 2003). In agreement with this earlier work, we
found that following the addition of UTP, ISC was about
twofold greater in CF MTEs compared with WT MTEs (Fig.
1A,E).
Previous experiments have determined that airway epithelial
Cl– channels can be regulated by both Ca2+ and by calmodulin-
dependent protein kinase II (CaMKII) (Chao et al., 1994;
Wagner et al., 1992; Chan et al., 1992; Fuller et al., 1994;
Ismailov et al., 1996), but the relative importance of the two
processes in regulating Cl– secretion in airway cells has so far
not been determined. This issue is significant to the current
study because it is the CaMKII-dependent process that is more
potently inhibited by Ins(3,4,5,6)P4 (Ho et al., 2001; Ismailov
et al., 1996). When cell-permeable KN93 was used to inhibit
CaMKII, ISC was reduced by 57±1% in WT cells and by
38±4% in CF cells (Fig. 1B,E). Therefore, CaMKII contributes
to a substantial proportion of transepithelial Cl– secretion in
both cell types.
We next examined the effect of Ins(3,4,5,6)P4 on
transepithelial Cl– secretion. We specifically elevated
intracellular levels of Ins(3,4,5,6)P4 by treating the
monolayer culture with a cell-permeable, bio-activatable
analogue of this inositol phosphate (Vajanaphanich et al.,
1994; Rudolf et al., 2003). This type of experiment has
previously only been performed in two cell lines, in T84
colonic epithelia and CFPAC-1 pancreatic epithelia
(Vajanaphanich et al., 1994; Carew et al., 2000). We were
able to show that 50 M Bt2Ins(3,4,5,6)P4/PM (the analogue
of Ins(3,4,5,6)P4) inhibited ISC by 40-50% in both CF and
WT MTEs (Fig. 1C,E). Restrictions on the availability of the
cell-permeant inositol phosphate analogues prevented us
from producing detailed dose-response relationships, but we
did find that increases in analogue concentration (up to 150
M) did not further inhibit ISC (data not shown). Thus, we
conclude that our routine experiments (Fig. 1) deploy a
maximally effective dose of Bt2Ins(3,4,5,6)P4/PM. The
inactive stereoisomer Bt2Ins(1,4,5,6)P4/PM did not affect
ISC (Fig. 1D,E).
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Inositol-phosphate levels in intact cells
We have used high performance liquid chromatography
(HPLC) to analyze the inositol-phosphate profile in confluent
MTEs during the same time-course as the transient peak of
chloride secretion (see above). Resting cells contained low
levels of InsP1, InsP2, InsP3 and InsP4 (Fig. 2A) that increased
dramatically upon PLC activation by the addition of UTP (Fig.
2B). Total PLC activity in WT and CF MTEs is shown in Fig.
3; these data were obtained by summation of levels of
Ins(1,4,5)P3 and all of its downstream metabolites (see Carew
et al., 2000). A bi-phasic stimulation of PLC was observed
(Fig. 3). During the initial phase, which was completed within
30 seconds of agonist addition, there was a five- to six-fold
increase in total inositol phosphates (Fig. 3). From 30 minutes
onwards, levels of inositol phosphates continued to increase,
but at a considerably slower rate (Fig. 3). Such an effect is
attributable to receptor desensitization (Menniti et al., 1992).
Both WT and CF cells showed a similar degree of PLC
activation (Fig. 3). Levels of Ins(1,4,5)P3, the intracellular
Ca2+-mobilizing signal (Berridge et al., 2000), were also
identical in both cell types (Fig. 4A). Phosphorylation of
Ins(1,4,5)P3 by isomer-specific 3-kinases, resulting in
Ins(1,3,4,5)P4, has been argued to regulate Ca2+ entry into cells
(Irvine, 1991). However, levels of Ins(1,3,4,5)P4 (Fig. 4B), and
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Fig. 2. Inositol-phosphate profile in MTEs. (A,B) Cells were labeled
for 4 days with [3H]inositol. Cells were treated with either (A)
vehicle or (B) 100 M UTP for 90 seconds and the inositol
phosphate levels were determined by HPLC as described in Materials
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its immediate metabolite, Ins(1,3,4)P3 (Fig. 4C) were also
similar in both cell types. The data in Figs 3 and 4, therefore,
show that there is no fundamental difference in the properties
of the PLC signaling system between the CF and WT MTEs.
Nevertheless, Ins(3,4,5,6)P4, which is in a metabolically
separate pool (Menniti et al., 1990), behaved differently in the
two cell types (Fig. 4D). Following purinergic activation, total
Ins(3,4,5,6)P4 levels increased more rapidly in the WT cells,
and reached levels that were 55-66% higher than those in CF
cells throughout 90 seconds of purinergic activation (P<0.03).
Note that Ins(1,4,5,6)P4, a constituent of many cells, co-elutes
with Ins(3,4,5,6)P4 upon HPLC (because the two
polyphosphates are enantiomers). Stereospecific, enzymatic
analysis of the Ins(3,4,5,6)P4 peak (Carew et al., 2000)
revealed (data not shown) that it contained <5% Ins(1,4,5,6)P4.
The CF condition and ITPK1 expression
We next considered that the significance of only Ins(3,4,5,6)P4
levels being different in the two cell types, probably reflects
this polyphosphate being in a discrete metabolic pool that is
regulated by ITPK1 (Menniti et al., 1990). Indeed, ITPK1 is
the only enzyme that can regulate cellular Ins(3,4,5,6)P4 levels.
We, therefore, investigated whether ITPK1 expression is
different in the two cell types.
Quantitative PCR data indicated that levels of ITPK1 RNA
were approximately twofold higher in WT cells compared with
CF cells (Fig. 5A). This effect was highly significant
(P<0.002). We were unable to reliably quantify ITPK1 protein
in cell lysates by western analysis (data not shown), because
our anti-human ITPK1 antibodies (Qian et al., 2005) were not
sufficiently sensitive against the denatured murine protein.
However, differences in ITPK1 protein levels in the two cell
types were confirmed following analysis by confocal
immunofluorescence microscopy (see below).
It is instructive to elaborate here about the significance of
the difference of ITPK1 expression in the two cell types. ITPK1
acts both as an Ins(3,4,5,6)P4 1-kinase and as an
Ins(1,3,4,5,6)P5 1-phosphatase (Ho et al., 2002). The greater
expression of ITPK1 in the WT cells was not associated with
changes in Ins(3,4,5,6)P4 levels in the unstimulated condition
(Fig. 4D), presumably because the poise of the 1-kinase / 1-
phosphatase cycle is not affected by increasing both catalytic
activities to the same extent. However, receptor-activation
specifically augments the InsP5 1-phosphatase activity at the
expense of the Ins(3,4,5,6)P4 1-kinase (Ho et al., 2002). Thus,
in receptor-activated cells, InsP5 dephosphorylation to
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Fig. 3. PLC activity in MTEs activated with UTP. WT () and CF
() cells were labeled for 4 days with [3H]inositol. Cells were
treated with vehicle (the zero time point) or UTP (for 30, 60 or 90
seconds). Individual inositol phosphate levels were determined by
HPLC as described in Materials and Methods. PLC activity is
computed from the increase in InsP1 + InsP2 + InsP3 + InsP4 but
excluding Ins(3,4,5,6)P4 (see Carew et al., 2000 for an explanation).
Data represent mean ± s.e.m. of five experiments.
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Fig. 4. Changes in levels of
Ins(1,4,5)P3, Ins(1,3,4,5)P4,
Ins(1,3,4)P3 and Ins(3,4,5,6)P4
following purinergic activation of
MTEs. WT () and CF ()
MTEs were labeled for 4 days
with [3H]inositol. Cells were
treated with vehicle (the zero time
point) or UTP (for 30, 60 or 90
seconds). Levels of the individual
inositol phosphate are as
indicated. (A), Ins(1,4,5)P3; (B),
Ins(1,3,4,5)P4; (C), Ins(1,3,4)P3;
(D), Ins(3,4,5,6)P4. Data represent
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Ins(3,4,5,6)P4 can be increased by a higher degree of ITPK1
expression.
ITPK1 not only regulates Ins(3,4,5,6)P4 metabolism, but
through its additional ability to phosphorylate Ins(1,3,4)P3
(Yang and Shears, 2000), it also serves to provide precursor
material for the synthesis of InsP5 and InsP6 (Shears, 1989;
Verbsky et al., 2005). Genetic manipulation of ITPK1 levels in
cultured cells – by RNA interference (RNAi) or by gene
overexpression – has been shown to dramatically alter levels
of InsP5 and InsP6 (Verbsky et al., 2005). However, the twofold
difference in ITPK1 expression between CF and WT MTEs
(Fig. 5A) did not affect InsP5 and InsP6 levels (Fig. 5B,C). This
finding offers physiological significance to small changes in
ITPK1 expression by virtue of it specifically controlling
Ins(3,4,5,6)P4 signaling strength during receptor activation.
Intracellular distribution of ITPK1
The early concept that soluble second messengers inevitably
freely equilibrate throughout the cell has more recently been
replaced by models in which there can sometimes be tight
compartmentalization of these signals, leading to localized
elevations in their levels within discrete subdomains (Zaccolo
et al., 2002). A fundamental prerequisite of this paradigm is
that the enzymes that synthesize and/or degrade the second
messenger must be restricted to a specific subcellular site
(Zaccolo et al., 2002). There is no prior evidence that this
qualification is met by ITPK1. For example, during its
purification from tissue homogenates, the enzyme is found to
be largely present in the soluble fraction (Shears, 1989; Wilson
and Majerus, 1996) and has therefore been thought to be
distributed throughout the cell. Furthermore, ITPK1 has no
known membrane-binding or lipid-binding domains, and is not
known to be covalently modified (e.g. by myristoylation) in a
manner that would facilitate its association with membranes.
However, the intracellular distribution of ITPK1 has not
previously been studied in intact
cells.
Using non-polarized cells grown
on glass coverslips, we were able to
detect ITPK1 in situ by confocal
immunofluorescence microscopy
(Fig. 6A) using our previously
described anti-ITPK1 antibodies
(Qian et al., 2005). We next validated
the specificity of the fluorescence
signal by demonstrating that it was
reduced in intensity by
approximately 60%, following
knock-down of ITPK1 expression by
RNAi (Fig. 6).
Changes in cellular architecture
during the process of cell
polarization can affect the
intracellular distribution of some
proteins, including some that
participate in inositol-phosphate
signaling (Colosetti et al., 2003).
When we studied the subcellular
distribution of ITPK1 in polarized
MTE monolayers, we found that the

































































Fig. 5. Differences in ITPK1 expression in WT and CF MTEs and its
impact upon synthesis of InsP5 and InsP6. (A-C) Quantitative PCR
was used to assess the degree of ITPK1 expression in the two cell
types, relative to the GAPDH control (A), as indicated in the
Materials and Methods. Data represent mean ± s.e.m. of four
experiments (P<0.002). Cellular levels of (B) InsP5 and (C) InsP6
(mean ± s.e.m. of five experiments) were determined as described in
Fig. 2; levels of these two polyphosphates did not change following
the addition of UTP (data not shown).
Fig. 6. Analysis by confocal immunofluorescence microscopy of the decrease in ITPK1
expression by RNAi in MTEs. (A,B) WT MTEs grown on glass cover slips were transfected
with either control, (A) non-targeting siRNA, or (B) ITPK1-specific siRNA as described in
Materials and Methods. Both horizontal (X-Y) optical scanning from Z-stacks, and vertical
(X-Z) scans are shown. Dotted lines show locations of accompanying perpendicular scans.
ITPK1 was visualized with Alexa Fluor 488 (green) and nuclei with DAPI (blue). Bar, 10
m. (C) Quantification of the intensity of the conjugated Alexa Fluor 488 throughout the
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to the apical pole of the cell (Fig. 7B). We also analyzed the
subcellular distribution of CFTR because it is already known
to be present in the apical membrane of polarized cells (Ameen
et al., 2000; Bertrand and Frizzell, 2003). In the WT MTEs,
the most intense CFTR signals were found at the apical
periphery of the cell (Fig. 7B). CFTR and ITPK1 showed only
limited colocalization, indicating that they largely occupy
distinct zones of the plasma membrane (Fig. 7D). Some CFTR
was also present in the lateral membranes, and some cytosolic
staining was also evident (Fig. 7C). The latter is consistent with
the idea that a subpool of CFTR resides in a vesicular
compartment (Bertrand and Frizzell, 2003; Ameen et al.,
2000). 
ITPK1 was also concentrated at the apical pole of the
polarized CF MTEs (Fig. 7F). There was a weaker signal for
ITPK1 in the polarized CF MTEs (Fig. 7F) compared with the
WT MTEs (Fig. 7C), which is consistent with the discovery
that these contain lower levels of the mRNA for ITPK1,
compared with the WT MTEs (see above). This difference in
fluorescence intensity was also observed in non-polarized cells
grown on cover slips: fluorescence
intensity in WT cells was 7.3±0.7
units/cell, whereas fluorescence
intensity in CF cells was 2.6±0.4
units/cell [mean ± standard error of the
mean (s.e.m.); for each cell type, the
data are derived from ten fields of view,
each of which contained 30-60 cells]. 
Discussion
In recent years, a new approach to
understanding CF pathogenesis has
emerged, which focuses on a search for
so-called modifier genes that may act
both to alter the severity of CF lung
disease, and to affect the efficacy of
therapeutic drugs (Boucher, 2004). This
work largely involves complex genetic
analysis (Cutting, 2005; Nagel, 2005).
In the current study, we have taken an
alternate, cell biological approach, and
we have demonstrated that ITPK1 has
the necessary characteristics to be
considered a candidate modifier gene.
ITPK1 synthesizes the intracellular
signaling molecule Ins(3,4,5,6)P4 (Ho et
al., 2002) that, we have demonstrated,
inhibits Ca2+-dependent Cl– secretion
from airway epithelial cells (Fig. 1).
Furthermore, we have shown that the
stimulation of MTEs with purinergic
agonists promotes increases in cellular
levels of Ins(3,4,5,6)P4 (Fig. 3). A
difference in the magnitude of the
Ins(3,4,5,6)P4 signal in WT and CF
MTEs (Fig. 4) coincided with a twofold
difference of ITPK1 expression in the
two cell types (Fig. 5). These data
provide a mechanistic explanation of the
previously puzzling observation that
CaCC activity is inherently upregulated
in CF MTEs (Tarran et al., 2002). This
view concerning the physiological
function of ITPK differs in emphasis
from that proposed by Majerus and
colleagues (Verbsky et al., 2005). The
latter authors concluded that pool sizes
of InsP5 and InsP6 are regulated by
ITPK1 – through the additional ability
of the enzyme to phosphorylate
Ins(1,3,4)P3 (Yang and Shears, 2000).
Fig. 7. Analysis by confocal immunofluorescence microscopy of ITPK1 localization in
polarized MTE monolayers. Cells were grown on membrane filters and prepared for
immunofluorescence confocal microscopy as described in Materials and Methods.
(A-G) Cells photographed in a horizontal (X-Y) optical section, with a corresponding vertical
(X-Z) optical scans; (A-D) WT cells, (E-G) CF monolayers. Nuclei were stained with DAPI
(A,E; blue), CFTR was stained with Alexa Fluor 546-labeled antibody (B; red) and ITPK1
was stained with Alexa Fluor 488-labeled antibody (C,F; green). The X-Z images of D and G












However, the Majerus group (Verbsky et al., 2005) came to this
conclusion after they dramatically altered ITPK1 levels by
either RNAi or by gene overexpression. By contrast, our data
indicate that relatively small (twofold) changes in ITPK1
expression can specifically regulate Ins(3,4,5,6)P4 levels
without affecting the levels of any other inositol phosphates
(Figs 4, 5).
Until recently, work by Majerus and colleagues (Sun et al.,
2003; Sun et al., 2002; Verbsky et al., 2005; Wilson et al.,
2001) would have offered a potential complication for our
hypothesis, because they proposed that ITPK1 has the ability
to phosphorylate proteins as well as to metabolize inositol
phosphate. However, we have recently demonstrated that the
protein kinase activity in Majerus’ preparations of recombinant
ITPK1 was entirely due to contaminants, rather than ITPK1
itself (Qian et al., 2005). Thus, we believe that any biological
differences in the two MTE cell lines that are due to ITPK1
expression are entirely mediated by the effect the enzyme has
on inositol phosphate turnover. 
We have also discovered an unexpected degree of structural
organization to the Ins(3,4,5,6)P4 signaling system, by
showing that ITPK1 is concentrated at the apical pole of the
polarized cell, which is where the CaCCs are also located
(Gabriel et al., 2000; Tarran et al., 2002). Ins(3,4,5,6)P4
synthesis, therefore, is concentrated near its site of action.
Localized metabolism of Ins(3,4,5,6)P4 can be enhanced if the
architecture of the cell interior presents structural barriers that
restrict the diffusion of cytosolic constituents (Rich et al.,
2000). It has been suggested that such barricades form by
invaginations of caveolae that protrude into the cell, or by the
placement of cell organelles in close proximity to the plasma
membrane (Rich et al., 2000). In the case of human airway
epithelia, there is a considerable enrichment of endoplasmic
reticulum and mitochondria near the apical domain (Ribeiro
et al., 2003); perhaps this slows down the movement of
Ins(3,4,5,6)P4 away from the plasma membrane. It is possible
that ITPK1 is compartmentalized at the apical membrane
through a lipid-binding motif or by specific association with
another protein that is itself membrane-bound. However, no
such interaction motifs have been identified in the amino-acid
sequence of ITPK1. Interestingly, we found that ITPK1 was
distributed throughout the cell following its overexpression in
the MTEs (data not shown). Thus, it seems likely that the
mechanism responsible for directing ITPK1 to the apical pole
is close to saturation just by endogenous expression levels of
this enzyme.
Cell-permeant antagonists of Ins(3,4,5,6)P4 are being
developed for the purpose of enhancing CaCC activity and
thereby improving salt- and fluid-secretion in CF airways
(Rudolf et al., 2003). Upregulation of CaCCs may have the
added benefit of secondarily inhibiting Na+ uptake, which
further assists this approach to CF therapy (Moody et al.,
2005). The degree of improvement in CaCC activity that can
be elicited by Ins(3,4,5,6)P4 antagonists would be expected to
be influenced by the extent to which endogenous Ins(3,4,5,6)P4
inhibits the Cl– channels, which in turn depends upon the
Ins(3,4,5,6)P4 concentration (Ho et al., 2001). Therefore, those
CF individuals with higher levels of ITPK1 expression
potentially stand to gain the most from therapy based on
Ins(3,4,5,6)P4 antagonists. Conversely, those CF individuals
with the lower levels of ITPK1 in airway cells would
Journal of Cell Science 119 (7)
synthesize less Ins(3,4,5,6)P4 following activation of PLC; in
these cells CaCCs would be expected to have higher activity,
so these particular patients might receive greater benefit from
the inhalation of purinergic agonists. We conclude that clinical
trials of these candidate pharmacological approaches to CF
should be correlated with ITPK1-expression profiling in order
to detect responsive patient subgroups.
Materials and Methods
Culture of mouse tracheal epithelial cell lines
The origin of the CF and WT mouse tracheal epithelial cells (designated MTE-18
and MTE-7b, respectively) has been described previously (Thomas et al., 2000).
For our experiments, CF cells were passaged 35-60 times and WT cells 40-66 times.
Cells were propagated in a humidified atmosphere of 95% air and 5% CO2 at 33°C,
in a medium consisting of a 1:1 mixture of Ham’s F-12 and 3T3 fibroblast-
conditioned medium (Thomas et al., 2000) supplemented with transferrin (2.5
g/ml), insulin (5 g/ml), epidermal growth factor (12.5 ng/ml), endothelial cell
growth supplement (1.875 g/ml), triiodothyronine (15 nM), hydrocortisone (0.5
M), and CaCl2 (0.5 mM).
Assay of inositol phosphate turnover
At 33°C, MTEs were seeded on 6-well plates coated with rat-tail collagen (BD
Biosciences; CA) in 1 ml medium supplemented with 100 Ci/ml [3H]inositol
(PerkinElmer Life Sciences, Boston, MA) for 4 days (medium was replaced every
2 days), at which point the cells were confluent. The culture medium was then
removed and the cells were washed twice in serum-free medium. Next, 20 mM LiCl
was added for an additional 20 minutes. At that point, UTP was added for various
length of time, following which cells were quenched with 1 ml of 0.6 M ice-cold
perchloric acid containing 0.2 mg/ml InsP6. The acid-soluble extract was neutralized
with 0.31 ml of 1M K2CO3 containing 5 mM Na2EDTA. Inositol phosphates were
then separated by HPLC using a 250 4.6-mm Synchropak Q100 SAX column
(Thompson Instruments, Chantilly, VA) and eluted with the following gradient,
generated by mixing water with buffer B [2 M (NH4)H2PO4 pH 3.35, with H3PO4]:
0-10 minutes, 0% buffer B; 11-124 minutes, 0–60% buffer B. The flow rate was 1
ml/minute. Typically, the eluate was mixed on-line with three volumes of
Monoflow-4 scintillant (National Diagnostics, Atlanta, GA). [3H]-labeled inositol
phosphates were detected with an in-line radiometric D515 flow scintillation
analyzer (FLO1; Packard Instrument Co., Meriden, CT). Levels of 3H-labeled
inositol phosphates were analyzed by the FLO1 software and normalized against
cell-lipid counts (Shears, 1997).
Bioelectric studies
MTEs were grown to confluence on transwell-COL inserts (Corning Costar,
Cambridge, MA). When required, cells were harvested from culture inserts using
0.1% (w/v) trypsin-EDTA, and reseeded at a concentration of 2104 cells/mm2 on
snapwell inserts (Corning Costar, Cambridge, MA) coated with human placenta
type VI collagen (Sigma-Aldrich). Bioelectric data were collected in Ussing
chambers. Monolayers were studied 3-4 days after confluence when the membrane
resistance was >100 /cm2. Once mounted in Ussing chambers, the serosal side of
the monolayer was bathed in medium at pH 7.4, containing 0.4 mM KH2PO4, 2.4
mM K2HPO4, 113 mM NaCl, 1.2 mM MgCl2, 1.1 mM CaCl2, 25 mM NaHCO3, 10
mM glucose. The mucosal medium (also pH 7.4) contained 0.4 mM KH2PO4, 2.4
mM K2HPO4, 15 mM Na-gluconate, 95 mM K-gluconate, 1.2 mM MgCl2, 1.1 mM
CaCl2, 25 mM NaHCO3, 10 mM glucose. The Ussing solutions were maintained at
33°C and gassed with a mixuture 95% O2 and 5% CO2. Where indicated,
Bt2Ins(3,4,5,6)P4/PM and Bt2Ins(1,4,5,6)P4/PM (SiChem, Bremen, Germany) were
added from stock solutions prepared in dried DMSO containing 5% (v/v) pluronic
F-127. The epithelial monolayers were continuously voltage-clamped (i.e. short-
circuited) to a transepithelial potential difference of zero. The magnitude and the
polarity of the applied short-circuit current (ISC) is a measure of the extent and
direction of the electrogenic ion flux across the epithelial layer. ISC was recorded
every 0.5 seconds, with a PowerLab/800 interface (AD Instruments Inc., Milford,
MA) on a PC running Chart v3.4. ASCII data for each trace were exported to
SigmaPlot (v8), whereupon the ISC value was set to zero at the time UTP was added
to the monolayers.
RNA interference
ITPK1 was depleted with siRNA oligonucleotide mixture (siGENOME
SMARTpool: Dharmacon, Inc. Lafayette, CO), the design of which was based on
the mouse ITPK1 sequence (GenBank accession number AK038913). siRNA
oligonucleotide sequences were verified by RT-PCR of cDNA obtained from WT
MTEs, using the following primers to amplify the entire coding region: 5-
GAATTCCATGCAGACCTTCCTGAAAGGGAAG-3 and 5-AGATCTCTA
CTGTGAGGAAGCCTTGGTGGCC-3. The ITPK1-specific siRNA (100 nM) and
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were transfected into WT MTEs with Lipofectamine 2000 (Life Technologies).
Transfected cells were analyzed 60 hours after transfection.
Quantitative PCR
RNA was prepared from confluent CF and WT MTEs using the RNeasy Mini Kit
(Qiagen Inc., CA); 5 g of total RNA was used for each reverse transcription of
cDNA, and 3 l of 1:5 diluted cDNA was used as a PCR-amplification template.
All reactions were performed using Sybr Green Master Mix (Applied Biosystems,
CA). PCR was carried out with the ABI PRISM 7900HT Sequence Detection
System (Applied Biosystems, CA). Amplification conditions and calibration curves
are as described previously (Deleu et al., 2006). The mouse GAPDH gene was
chosen as an internal control for quantitative PCR. These primer sequences were:
5-GCAAAGTGGAGATTGTTGCCAT-3 and 5-CCTTGACTGTGCCGTTGAA-
TTT-3. ITPK1 primer sequences were as follows: 5-CAGAGTGGCTCATG-
GAACCAA-3; 5-CAGGACAGCATTGTGGTTGATG-3.
Confocal immunofluorescence microscopy.
MTEs were grown to confluence on Transwell-Col culture chambers with a
diameter of 12 mm. After 48 hours of incubation, cells were washed with
Dulbecco’s phosphate buffered saline (DPBS, without Ca2+ and Mg2+) and fixed
in 3% paraformaldehye in 25 mM HEPES, 10 mM EGTA, 60 mM PIPES, 4 mM
MgSO4, (pH 7.0) for 20 minutes at 4°C. After several washes in DPBS, cells
were permeablized by 1% Triton X-100 in DPBS for 5 minutes at room
temperature, then incubated in PBS containing 1% BSA for 20-30 minutes at
room temperature. For the studies shown herein, cells were either incubated in
PBS containing 1% BSA and either a 1:500 dilution of affinity-purified rabbit
anti-human ITPK1 antibody (Qian et al., 2005) or a 1:200 dilution of CFTR
mouse monoclonal antibody (NeoMarkers, Fremont, CA) for 2 hours at room
temperature. Thereafter, the cells were washed and incubated 1 hour in PBS with
1% BSA containing Alexa-Fluor-488-conjugated or Alexa-Fluor-546-conjugated
secondary antibodies (Invitrogen, Carlsbad, CA) to visualize ITPK1 or CFTR,
respectively. Cells were then washed and incubated with 4,6-diamidino-2-
phenylindole, dilactate (DAPI, 1:15,000 dilution) (Sigma, St Louis, MO) for 10
minutes. The fixed cells on chambers were then mounted in PBS buffer. A laser
scanning confocal microscope with two-photon excitation option (LSM 510 NLO
mounted on Axiovert 100M microscope, Carl Zeiss, Inc.) was used to obtain XY
and XZ fluorescence images. The objective lenses used were the C-Apochromat
40/1.2 water immersion for membrane insert imaging in XY and XZ mode, and
the Plan-Apo 63 oil immersion NA 1.4 for Z-stack imaging of cells grown on
cover glass. Images from different probes were obtained sequentially to
maximize fluorescence detection. For the Alexa Fluor probes, the 488 nm Ar-
laser and the 543 nm HeNe-laser were used for excitation, and the emission filters
were BP500-550 and LP560 for the green and red probes, respectively. For DAPI,
two-photon excitation was achieved with the Verdi-Mira laser (Coherent Laser,
Carlsbad, CA) tuned to 750 nm, and the emission filter was BP435-485. The
pinholes used for confocal imaging were set to ~1 Airy Unit to approximately
match the Z-resolution of two-photon excitation, i.e. ~0.9 m for the 40 water
lens (membrane imaging), and ~0.7 m for the 63 oil lens (coverglass
imaging). For each Z-stack, ten image slices were acquired at regular intervals
of 1.9 m in Z, to sample the total thickness of the cells, which was no more
than 15 m. For quantitation of ITPK1 expression per cell from Z-stacks, a ratio
was performed of the background-subtracted, average pixel intensity of the
conjugated Alexa Fluor 488 throughout the stack volume, to the number of cells
visually apparent from a rotating projection of the corresponding DAPI-stained
(nuclei) Z-stack. Membrane images used for the figures have been digitally
smoothed with a 33 filter. Contrast enhancement was performed separately on
all images shown, so that they all have approximately the same background and
the same level of saturation. The software used for processing and analysis was
Zeiss LSM Image Examiner (licensed) version 3.2.
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